Three rapid molecular Truenat assays for initial diagnosis of tuberculosis ( TB) and subsequent identification of rifampicin resistance in adults and children with signs and symptoms of pulmonary TB have now been endorsed by the World Health Organization (WHO).
This according to a release released by the Medical Research Council of India (ICMR) along with the Foundation for Innovative New Diagnostics (FIND) and Molbio Diagnostics.
Following recommendation from ICMR, Truenat assays have now been integrated into the India National TB Elimination Program (NTEP).
Only Truenat MTB and Truenat MTB Plus identify mycobacterium tuberculosis bacteria for diagnosis of TB, while Truenat MTB-RIF Dx detects resistance to rifampicin, the first-line therapy most widely used. The three experiments are run on the Truenat lightweight, battery-operated system and produce results in less than an hour.